Association Between Sexual Dysfunction and Dose of Atypical Antipsychotics: Essential to Learn the Basics.

Abstract

There is paucity of data on sexual dysfunction associated with atypical antipsychotics in Indian population. We estimated the prevalence of sexual dysfunction and assessed dose dependency, if any, in patients on monotherapy of atypical antipsychotics. This cross-sectional study analyzed the data from patients with F20 to F29 (International Classification of Diseases 10th Revision, ICD-10) receiving monotherapy of risperidone (group1), olanzapine (group2), or quetiapine (group3) for at least 4weeks. The sexual function of participants was assessed using Arizona sexual experiences (ASEX) scale. Chlorpromazine (CPZ) equivalent dose and doses in terms of dose years were calculated. Kruskal-Wallis test, Mann-Whitney U-test, and Pearson correlation were used for analysis. Of the 154 subjects, 65.58% were males, with 44%, 48%, and 8% receiving risperidone, olanzapine, and quetiapine, respectively. The mean duration of treatment was 20.9weeks. Lower ASEX scores were reported with quetiapine. The differences in mean ASEX scores between groups1 and 2 were statistically significant for sex drive (P=.016), sexual arousal (P=.025), and overall score (P=.037). Sexual dysfunction was more frequent with risperidone (48.5%) than with olanzapine (28.4%) and quetiapine (0%). In group1, the duration of therapy positively correlated with the mean scores of sexual desire (P=.003) and arousal (P=.033), but this was not the case for group2 (receiving olanzapine). The mean CPZ equivalent doses were comparable between the groups (P=.064); those receiving <200mg CPZ dose equivalents showed greater sexual impairment. We conclude that the occurrence of atypical antipsychotic-induced sexual dysfunction is not dose dependent. Olanzapine has a better safety profile in terms of sexual dysfunction, whereas the data reflecting the experience with quetiapine are insufficient.